Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05130567
Other study ID # LP-128-CN101
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date November 19, 2021
Est. completion date December 30, 2024

Study information

Verified date February 2024
Source Guangzhou Lupeng Pharmaceutical Company LTD.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects


Description:

This trial includes single dose and multiple dose phases. The single-dose phase included six dose cohorts. Based on the safety and pharmacokinetic results of single-dose study, approximately 2 doses will be selected to conduct multiple-dose study. The primary study objectives are to evaluate the safety, tolerability, and pharmacokinetic characteristics of LP-128 capsules in healthy subjects after single and multiple dosing.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 104
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Subjects have no history of serious digestive system, central nervous system, cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal and muscular system, blood system disease and cancer - Subjects (including partners) are willing to take effective contraception measures during study and within 3 months after last dose - Male and female healthy subjects aged 18 to 55 years old - Male subjects weigh = 50 kg, and female subjects weigh = 45 kg - Subjects able to understand and comply with study requirements - Willing to sign the informed consent and fully understand the content, process and possible adverse reactions of the trial Exclusion Criteria: - Abnormal vital signs, physical examination or laboratory tests with clinical significance - Abnormal ECG, chest X-ray, abdominal ultrasound or echocardiography with clinical significance - Positive screening for viral hepatitis, HIV and syphilis - Subjects who have taken any drugs or health care products within 14 or 28 days before administration the study drug; or subjects who have consumed tea or alcohol-containing food product within 24hrs before administration the study drug - Subjects who have a history of dysphagia or condition may affect drug absorption, distribution, metabolism and excretion - Female subjects are breastfeeding or pregnant - Subjects who have a history of drug/alcohol/tobacco abuse - Subjects who have had a blood donation or massive blood loss within three months before screening; or had major surgery within six months before screening - Subjects who have participated in other clinical trial within three months before screening - Subjects have special dietary requirements or cannot tolerate a standard meal - Subjects who are not suitable for this trial based on the assessment of investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LP-128 capsules
Oral dosing with LP-128 capsules
Other:
Matching Placebo
Oral dosing with placebo capsules to match LP-128 capsules.

Locations

Country Name City State
China NanFang Hospital of Southern Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangzhou Lupeng Pharmaceutical Company LTD.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the plasma concentration-time curve (AUC) of LP-128 Plasma samples were collected at different points for pharmacokinetic analysis Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively
Primary Apparent terminal phase half-life (T1/2) of LP-128 Plasma samples were collected at different points for pharmacokinetic analysis Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively
Primary Maximum observed plasma concentration (Cmax) of LP-128 Plasma samples were collected at different points for pharmacokinetic analysis Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively
Primary Adverse events of LP-128 The incidence and severity of adverse events as assessed by NCI CTCAE v5.0. Up to 28 days
Secondary Excretion of LP-128 in urine Urine samples will be collected at different points for pharmacokinetic analysis Up to 4 days
Secondary Excretion of LP-128 in feces feces samples will be collected at different points for pharmacokinetic analysis Up to 4 days
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360892 - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography N/A